Guggenheim Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Guggenheim Capital’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-14,558	Closed	-$548K	–	2277
2021 Q1	$548K	Buy	+14,558	New	+$363K	﹤0.01%	1673
2018 Q1	–	Sell	-58,501	Closed	-$1.28M	–	2827
2017 Q4	$1.28M	Sell	58,501 -10,135	-15%	-$326K	﹤0.01%	1940
2017 Q3	$2.81M	Sell	68,636 -1,007	-1%	-$31.6K	0.01%	1427
2017 Q2	$2.1M	Buy	69,643 +12,234	+21%	+$382K	0.01%	1593
2017 Q1	$2.08M	Buy	57,409 +8,471	+17%	+$373K	0.01%	1638
2016 Q4	$2.45M	Sell	48,938 -3,739	-7%	-$196K	0.01%	1519
2016 Q3	$2.77M	Sell	52,677 -5,522	-9%	-$264K	0.01%	1393
2016 Q2	$2.41M	Buy	+58,199	New	+$2.53M	0.01%	1447

Guggenheim Capital's FPRX Position: Q2 2021 in Review

Guggenheim Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 14,558 shares — an estimated $548K sold.

Guggenheim Capital first reported a position in FPRX in Q2 2016 and held it in 8 quarters. The position peaked at $2.81M in Q3 2017. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

Guggenheim Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
Guggenheim Capital sold 14,558 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $548K.
Guggenheim Capital first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 8 quarters.
Guggenheim Capital's Five Prime Therapeutics, Inc. position peaked at $2.81M in Q3 2017.
0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Guggenheim Capital's 13F filing for Q2 2021, filed 13 Aug 2021.